Key result
Percutaneous LAAC offers an evolving alternative to oral anticoagulants for stroke prevention in AF.
Why the study?
Three recent randomized trials (OPTION, CLOSURE-AF, and CHAMPION-AF) have attempted to address whether percutaneous left atrial appendage closure (LAAC) is a valid alternative to oral anticoagulant treatment in patients with atrial fibrillation (AF).
This paper discusses three recent randomized trials (OPTION, CLOSURE-AF, and CHAMPION-AF) evaluating whether percutaneous left atrial appendage closure is a valid alternative to oral anticoagulation in patients with atrial fibrillation.
Three recent randomized trials have attempted to address the question on whether left atrial appendage closure (LAAC) is a valid alternative to oral anticoagulant treatment in patients with atrial fibrillation (AF): the OPTION trial, the CLOSURE-AF trial and the CHAMPION-AF trial.
No takes yet. Share an insight, caveat, or question.
Vittorio Pengo (2026) studied this question. Percutaneous left atrial appendage closure has been evaluated as an alternative to oral anticoagulation in atrial fibrillation across the OPTION, CLOSURE-AF, and CHAMPION-AF trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: